옵션 체인은 다양한 행사가격과 만기일에 대한 의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 에 대한 시장 심리를 평가합니다..

 (JNVR) 주식, 옵션 체인

Palantir, Intel, Arista, Occidental, And Tesla: Why Are These 5 Stocks On Investors' Radars Today

Equities

News

Markets

BABA

JNVR

TSLA

수요일(9일) 괄목할 만한 상승세를 보였던 미국 증시는 목요일(10일)에 급격한 하락세를 보였다. 투자자들은 계속되는 경제 불확실성 속에서 도널드 트럼프 대통령의 90일 관세 유예의 의미를 평가하면서 신중한 모습을 보였다.

목요일 주목받은 주식: 알리바바, JP모건, 카맥스, 재노버 및 테슬라

DeFi Development Corp

WIIM

WLDS

WLDS stock has given up its prior gain. Wearable Devices shares were trading higher after the company announced that the United States Patent and Trademark Office has granted a continuation of its patent titled "Gesture and Voice-Controlled Interface Device".

GLJ Research analyst Gordon Johnson upgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Sell to Hold and maintains the price target from $7.78 to $7.78.

Upgrades

Price Target

Analyst Ratings

GLJ Research Upgrades Sunrun to Hold, Maintains Price Target to $7.78

Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) from Hold to Buy and announces $12 price target.

BLRX

Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target

<ul>
<li>NVDA</li>
<li>GLD</li>
<li>TSLA</li>
<li>GRND</li>
<li>UNH</li>
<li>BULL</li>
<li>GOOGL</li>
<li>ULTA</li>
<li>DELL</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

BULL

DELL

GOOGL

GRND

NVDA

ULTA

Top 10 Trending Stocks On WallStreetBets As Of May 30, 2025 (Via Swaggy Stocks)

GLJ Research analyst Gordon Johnson upgrades SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Sell to Hold and maintains the price target from $6.9 to $6.9.

SEDG

GLJ Research Upgrades SolarEdge Technologies to Hold, Maintains Price Target to $6.9

Energy company EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) shares are trading lower premarket on Friday. The firm inked a deal to acquire Encino Acquisition Partners (EAP) for <a href="https://www.benzinga.com/pressreleases/25/05/n45691870/eog-resources-to-acquire-encino-acquisition-partners-from-cpp-investments-and-encino-energy-streng" target="_blank" rel="noreferrer noopener">$5.6 billion, including EAP&#8217;s net debt</a>.
EOG agreed to pay the sellers, Canada Pension Plan Investment Board (CPP) and Encino Energy, with cash and debt. The purchase price includes $3.5 billion in new debt and $2.1 billion in cash.
The company expects the transaction to close in the latter half of 2025, upon clearance under the Hart-Scott-Rodino Act.
EOG&#8217;s portfolio will grow by 675,000 net core acres, expanding its Utica position to 1.1 million net acres. In addition:
<ul class="wp-block-list">
<li>EOG's undeveloped net resource gets a boost of over two billion barrels of oil equivalent</li>
<li>Combined production will reach 275,000 BOE/day</li>
<li>A continuous position of 485,000 net acres that averages 65% liquids production.</li>
<li>In the natural gas window, the deal adds 330,000 net acres</li>
</ul>
Annually, the acquisition is expected to increase 2025 EBITDA by 10% and cash flow from <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">operations and free cash flow by 9%</a>.
EOG expects to achieve more than $150 million in synergies during the first year, primarily driven by reductions in capital, operating, and debt financing costs.
Dividend Boost: The board declared a dividend of $1.02 per share, up 5%, representing an indicated annual rate of $4.08.
This dividend is payable on Oct. 31 to shareholders of record as of Oct. 17.
As of March 31, EOG&#8217;s cash and cash <a target="_blank" href="https://www.benzinga.com//node/45150645" rel="noreferrer noopener">equivalent stood at $6.6 billion</a>.
Price Action: EOG shares are down 1.94% at $107.75 premarket at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45665087/bp-announces-first-gas-at-mento-off-trinidads-southeast-coast" target="_blank" rel="noreferrer noopener">BP Announces First Gas At Mento Off Trinidad&#8217;s Southeast Coast</a></li>
</ul>
Image: Shutterstock

Large Cap

Guidance

Movers

EOG Strikes $5.6B Deal To Expand Utica Footprint, Boosts Dividend

Jefferies analyst Brent Thill upgrades Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) from Hold to Buy and raises the price target from $22 to $29.

Jefferies Upgrades Unity Software to Buy, Raises Price Target to $29

As of May 30, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Douglas Elliman Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, Douglas Elliman reported better-than-expected first-quarter sales results. &#8220;Our performance in the first quarter highlights the strength of our luxury brand and the incredible efforts of our agents, employees and leadership team,&#8221; said Michael S. Liebowitz, Chief Executive Officer of Douglas Elliman Inc. &#8220;By focusing on high-impact areas like Development Marketing, we&#8217;re driving growth and reinforcing our position as the leader in the luxury market – delivering our highest first-quarter revenue since 2022 with significant reductions in operating losses.&#8221; The company's stock jumped around 76% over the past month and has a 52-week high of $3.20.</li>
<li>RSI Value: 79.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>DOUG Price Action: Shares of Douglas Elliman fell 1% to close at $2.92 on Thursday.</li>
<li>Edge Stock Ratings: 97.12 Momentum score with Value at 65.91. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/doug"><img loading="lazy" decoding="async" width="463" height="160" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29233739/image-404.png" alt="" class="wp-image-932492" style="width:330px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29233739/image-404.png 463w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29233739/image-404-300x104.png 300w" sizes="(max-width: 463px) 100vw, 463px" /></a></figure>
<h3 class="wp-block-heading">Paramount Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGRE#NYSE">PGRE</a>)</h3>
<ul class="wp-block-list">
<li>On May 20, Evercore ISI Group analyst Steve Sakwa upgraded Paramount Group from In-Line to Outperform and raised the price target from $4.5 to $8. The company's stock gained around 42% over the past month and <a href="https://www.benzinga.com/quote/PGRE">has a 52-week high</a> of $6.34.</li>
<li>RSI Value: 78</li>
<li>PGRE Price Action: Shares of Paramount fell 2.6% to close at $6.09 on Thursday.</li>
<li></li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

DOUG

PGRE

Top 2 Real Estate Stocks That May Implode In Q2

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Friday.
Shares of Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ESTC/earnings">fourth-quarter results.</a>
Elastic posted adjusted earnings of 47 cents per share, beating market estimates of 37 cents per share. The company's sales came in at $388.43 million versus expectations of $380.36 million.
Elastic said it sees first-quarter adjusted EPS of 41 to 43 cents on sales of $396.00 million to $398.00 million.
Elastic shares dipped 9.7% to $83.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) dipped 13.7% to $24.10 in pre-market trading after the company reported first-quarter financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.</li>
<li>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) declined 10% to $72.00 in pre-market trading following second-quarter results.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 8.8% to $552.00 in pre-market trading after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study did not.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) fell 8.2% to $20.49 in pre-market trading. Newsmax filed for resale of up to 121 million shares of Class B common stock by selling stockholder.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) declined 7.4% to $40.01 in pre-market trading.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) fell 7.2% to $10.38 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Venu Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VENU#NASDAQ">VENU</a>) dipped 6.1% to $12.10 in pre-market trading after gaining 8% on Thursday. Venu Holding recently announced it will join the Russell 3000 Index.</li>
<li>NetApp, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) dipped 5.2% to $94.00 in pre-market trading after the company issued soft first-quarter guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

ESTC

IONQ

NMAX

NTAP

REGN

VENU

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Cantor Fitzgerald analyst Matthew Prisco reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Neutral and maintains $60 price target.

Reiteration

MRVL

Cantor Fitzgerald Reiterates Neutral on Marvell Tech, Maintains $60 Price Target

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">101.20</td>
<td align="right">0.22</td>
<td align="right">0.21</td>
<td>794</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.18</td>
<td align="right">0.07</td>
<td align="right">0.08</td>
<td>8.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">85.7000</td>
<td align="right">-0.63</td>
<td align="right">-0.73</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">81.7700</td>
<td align="right">-0.49</td>
<td align="right">-0.60</td>
<td>130.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.5900</td>
<td align="right">-0.26</td>
<td align="right">-0.52</td>
<td>192.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.0100</td>
<td align="right">-0.72</td>
<td align="right">-0.51</td>
<td>2.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.9500</td>
<td align="right">-1.02</td>
<td align="right">-0.48</td>
<td>7.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.7900</td>
<td align="right">-0.57</td>
<td align="right">-0.44</td>
<td>3.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.7505</td>
<td align="right">-0.34</td>
<td align="right">-0.42</td>
<td>1.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">230.7500</td>
<td align="right">-0.88</td>
<td align="right">-0.38</td>
<td>25.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.5400</td>
<td align="right">-0.15</td>
<td align="right">-0.36</td>
<td>1.9K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 30, 2025

Wells Fargo analyst Brandon Couillard initiates coverage on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Overweight rating and announces Price Target of $59.

Initiation

TECH

Wells Fargo Initiates Coverage On Bio-Techne with Overweight Rating, Announces Price Target of $59

The U.S. Congress is reviewing a provision in the &#8216;Big, Beautiful Bill&#8217; that would grant President Donald Trump the authority to impose retaliatory taxes on countries targeting major U.S. tech companies with digital service taxes.
What Happened:&nbsp;The provision would allow Trump to impose taxes on foreign companies and residents doing business in the U.S., reported&nbsp;Reuters&nbsp;on Friday. This provision, Section 899, could potentially generate&nbsp;$116 billion over the next&nbsp;10 years.
&#8220;If&nbsp;foreign countries want to come&nbsp;in the United States and&nbsp;tax U.S. businesses, then those&nbsp;foreign-based businesses ought to be&nbsp;taxed as well,&#8221; said Representative&nbsp;Ron Estes,&nbsp;a Kansas Republican who was instrumental in drafting the provision.
The bill, narrowly approved by the <a href="https://www.benzinga.com/25/05/45582778/trumps-big-beautiful-bill-passes-house-what-it-means-for-taxes-student-loans-medicaid-and-more">House of Representatives on May 22</a>, is now moving to the Senate. It features several of Trump's core priorities, including stricter immigration measures, an extension of the 2017 tax cuts, and the rollback of certain green energy incentives. Despite this, experts caution that such retaliatory taxes could discourage foreign investment in the U.S.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45685544/scott-bessent-says-us-china-trade-talks-at-stalemate-need-trump-and-xi-jinping-touch-to-break-the-deadlock" target="_blank" rel="noreferrer noopener">Scott Bessent Says US-China Trade Talks At Stalemate, Need Trump And Xi Jinping Touch To Break The Deadlock</a>
Why It Matters: The provision in the tax bill comes in the wake of several countries, including Britain and Italy, announcing or considering digital service taxes on U.S. tech giants. The levies have been drawn bipartisan criticism. Germany is <a href="https://www.benzinga.com/25/05/45689009/germany-considers-10-digital-tax-on-tech-titans-alphabet-and-meta-report">contemplating </a>a 10% tax on major online platforms, including Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) and Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). This move could further escalate trade tensions with the U.S.
Earlier in May, the Trump administration had&nbsp;<a href="https://www.benzinga.com/25/05/45466937/us-targets-european-digital-rules-in-free-speech-campaign-defending-american-big-tech">criticized </a>Europe&#8217;s digital regulations, arguing that they posed a risk to free speech and American commercial interests. The U.S. State Department had initiated an effort to identify European government attempts to restrict free speech, focusing on the EU&#8217;s legislation that sets standards for tech giants to regulate online content.
These developments indicate a growing rift between the U.S. and its European allies over digital taxation and regulation, with the proposed provision in the tax bill potentially escalating these tensions.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/cannabis/25/05/45691518/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104150" target="_blank" rel="noreferrer noopener">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150 &#8211; Benzinga</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Joey Sussman / Shutterstock.com

Politics

GOOG

Trump's 'Big, Beautiful Bill' Could Allow Him To Hit Back With Retaliatory Taxes On Countries Targeting US Tech Giants

Cantor Fitzgerald analyst Jonathan Ruykhaver maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $275 to $290.

Cantor Fitzgerald Maintains Overweight on Zscaler, Raises Price Target to $290

ESS Tech, Inc. ("ESS" or the "Company") ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2Fgwh&amp;,%20esheet=54262361&amp;,%20newsitemid=20250530012137&amp;,%20lan=en-US&amp;,%20anchor=NYSE%3AGWH&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">GWH</a>), a leading manufacturer of iron flow long-duration energy storage (LDES) systems for commercial- and utility-scale applications, today provided a business update and the continued execution of its strategic plan focused around the Energy Base product. Previously, ESS announced the potential need to take certain workforce actions in the event it was unable to raise capital to enable the Company to avoid or postpone a shutdown. ESS subsequently received sufficient capital not anticipated in the ordinary course of business to continue operations at its Wilsonville facility in the near term, though it will still undertake actions to judiciously manage its operating expenses. "I am pleased to report this important development and the continuation of our strategic pivot and delivery of a scalable Energy Base solution manufactured here in the United States to support unprecedented growth in energy demand and the critical need for grid reliability and resiliency," said Kelly Goodman, Interim CEO of ESS.
ESS also recently executed several actions to further implement this plan and deepen collaboration with key partners. The Company closed orders for the sale of four Energy Warehouses as part of its ongoing dual strategy to move existing inventory and pivot to a focused Energy Base product offering. ESS intends to sell the associated Advanced Manufacturing Production Tax Credits (PTC) from the equipment sales this quarter. The Company is continuing discussions with potential capital providers and exploring all available financing options to support its repositioned business plan, including to close key customer contracts for its proprietary 10+ hour Energy Base product.

ESS Tech Announces Continued Execution Of Strategic Plan Focused Around Energy Base Product

Cantor Fitzgerald analyst Thomas Blakey maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Neutral and lowers the price target from $109 to $92.

Cantor Fitzgerald Maintains Neutral on Elastic, Lowers Price Target to $92

GrabAGun will leverage Compatio's AI functionality across the Company's site to optimize product recommendations, compatibility and optionality for customers
Metroplex Trading Company, LLC (doing business as GrabAGun) (the "Company" or "GrabAGun"), an online retailer of firearms, ammunition and related accessories that previously entered into a business combination agreement (the "Business Combination Agreement") with Colombier Acquisition Corp. II ("Colombier II") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLBR#NYSE">CLBR</a>), today announced an agreement with Compatio AI ("Compatio"), enabling GrabAGun customers access to an industry-first digital solution for product customization on the GrabAGun website.
GrabAGun will leverage Compatio's Config tool to streamline complex customizations of products such as modern sporting rifles, enabling unprecedented optimization across brands, features, technical specifications and inventory availability. Compatio's capabilities will be fully integrated into the GrabAGun website, along with a real-time bundle customization tool. This capability further enhances the user experience by providing a tailored guide to help customers determine the product configuration that is the best fit for them.
"We are thrilled to announce our collaboration with Compatio to deliver what we believe will be the most advanced product customization engine in the retail firearms industry," said Marc Nemati, Chief Executive Officer of GrabAGun. "Deploying Compatio's product configuration tool further elevates the customer experience, helping to drive both engagement and sales. Coupled with our proprietary tech stack and mobile-focused approach, GrabAGun remains well positioned with the fastest growing segments of the firearms market, Millennial and Gen Z buyers."

CLBR

GrabAGun Announces Agreement To Deliver Digital Solution for Product Customization On The GrabAGun Website

Management

MYSZ

MySize Appoints Borja Cembrero Saralegui As Chief Growth Officer

Processa Pharmaceuticals, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa's pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances.

PCSA

Processa Pharma Announces Acceptance Of Three Abstracts For 2025 ASCO Annual Meeting; Abstracts Highlight Processa's Pipeline Of NGC Drug Candidates

Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy for epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">EGFR tyrosine kinase inhibitor (TKI)</a>.
The trial met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS).
At the prespecified primary data analysis, ivonescimab, in combination with chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a hazard ratio of 0.52.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44463128/analyst-initiates-coverage-on-undervalued-summit-therapeutics" rel="noreferrer noopener">Analyst Initiates Coverage On &#8216;Undervalued&#8217; Summit Therapeutics</a>
Ivonescimab, in combination with chemotherapy, showed a positive trend in OS in the primary analysis but did not achieve a statistically significant benefit, with a hazard ratio of 0.79 (p=0.057).
No new safety signals were noted in this Phase 3 study. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported for 56.9% of patients in the ivonescimab + chemotherapy arm vs. 50.0% with chemotherapy alone.
Fatal TEAEs (excluding disease progression) were reported for 1.8% of patients in the ivonescimab + chemotherapy arm vs. 2.8% in those patients receiving chemotherapy alone.
The safety profile of ivonescimab + chemotherapy was acceptable and manageable in the context of the observed clinical benefit.
Based on the HARMONi clinical trial results, Summit intends to file a Biologics License Application (BLA) to seek approval for ivonescimab plus chemotherapy in this setting.
Based on discussions with the FDA, Summit will consider the timing of the filing of this BLA.
The FDA noted that a statistically significant overall survival benefit is necessary to support marketing authorization, which will weigh into Summit&#8217;s considerations regarding the timing of a potential BLA filing.
In April, Summit Therapeutics noted that&nbsp;Akeso, Inc.&nbsp;announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45046531/why-is-summit-therapeutics-stock-trading-higher-on-monday" rel="noreferrer noopener">HARMONi-2 or AK112-303</a>.
Akeso announced the results of this interim overall survival analysis included a clinically meaningful hazard ratio of 0.777.
Summit Therapeutics&#8217; partner, Akeso, Inc., released topline data from the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Phase 3 HARMONi-6/K112-306 trial</a>.
The trial met its primary endpoint of progression-free survival (PFS).
At a prespecified interim analysis conducted by an Independent Data Monitoring Committee, ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to BeiGene, Ltd&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCE#NASDAQ">ONCE</a>) Tevimbra (tislelizumab) plus chemotherapy.
The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors.
Price Action: At the last check on Friday, SMMT stock was down 12.3% to $23 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45679204/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">Apple iPhone Shipment Could Decline In 2025 As Tariff, Competition Play Spoil Sport: IDC</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

ONCE

SMMT

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Financing

Press Releases

DeFi Development Corp. Announces Closing of $24 Million Private Placement

DeFi Development Corp. Purchases 20,473 Solana (SOL), Bringing Treasury Holdings to 420,690 SOL

DeFi Development Corp. Purchases Record 172,670 SOL, Surpasses $100M in Treasury Holdings

DeFi Development Corp. to Host X Spaces Event: "Fireside Chat with John Han (CFO), DK (Head of IR), and Pete Humiston (Head of Research and Content)"

Earnings

DeFi Development Corp. Reports First Quarter 2025 Financial Results and Provides Strategic Update on Solana Treasury Activity

DeFi Development Corp. Introduces New Treasury Strategy Compensation Plan Tied to SOL Per Share (SPS)

DeFi Development Corp. Purchases 16,447 SOL, Becomes Leading Solana Treasury Company

DeFi Dev Corp. and BONK Make History with First Public Company and Community Memecoin Validator Partnership

DeFi Dev Corp. Announces Adoption of Liquid Staking Token Technology Developed by Sanctum; DFDV Becomes the First Public Company to Invest in Liquid Staking Tokens

DeFi Development Corp. to Host X Spaces Event: "Validators 101: Powering Solana's Future"

DFDV

Janover

Comments

(JNVR) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌